GENETIC MARKERS IN LYMPHOMA a practical overview P. Heimann Dpt of Medical Genetics Erasme Hospital - Bordet Institute.

Slides:



Advertisements
Similar presentations
High Resolution studies
Advertisements

STATUS OF DETECTION OF MINIMAL
The WHO Classification of Hematological Malignancies
Amy Y-Y Chen, MD Andrew Chen, MD
Chapter 29 Essential Concepts in Molecular Pathology Companion site for Molecular Pathology Author: William B. Coleman and Gregory J. Tsongalis.
Molecular Haemato-Oncology at Bristol Genetics Laboratory
A comparison of the frequency of common lymphoma- associated gene rearrangements among B-Post transplant lymphoproliferative disorders (B-PTLD), B-cell.
Molecular Path of the GI tract Dr Shaun Walsh. Mutation analysis in Tumours A new challenge for oncologists, surgeons pathologists and for patients I’m.
Minimal Residual Disease in Hematologic Neoplasms Lloyd M. Stoolman, M.D. Professor of Pathology and Director, Clinical and Research Flow Cytometry Laboratories.
Susanna Akiki WMRGL 2009 Acute Promyelocytic Leukemia with t(15;17) (q22;q21) developing inv(16)(p13q22) secondary AML.
Edoardo Pescarmona Dipartimento di Medicina Sperimentale
Molecular Testing of Lymphomas John Goodlad Department of Pathology Western General Hospital & University of Edinburgh Edinburgh RCPath.
Research Techniques Made Simple: T-Cell Receptor Gene Rearrangement
MANTLE CELL Lymphoma (WITH EMPHASIS ON THE gi TRACT)
Proposed WHO Classification of Lymphoid neoplasm
TODAY B CELL DEVELOPMENT.
Sabine Franke, PhD CHU Liège, Centre for Human Genetics 20/04/12 ULG Acquired alterations of IGH and TCR loci in lymphoproliferative disorders Interuniversity.
Clinical Genetics M. Kent Froberg, MD Purpose This lecture is designed to illustrate two examples of the use of molecular genetics in the clinical.
Assay for 14;18 Translocation PCR/Blot Hybridization
Hematology and Hematologic Malignancies Cancer of the formed elements of the blood.
Generation of diversity in lymphocyte antigen receptors Jan. 31, Feb. 2 & 5 Chapter 4.
Lymphoma Dr. Raid Jastania Dec By the end of this session you should be able to: –Discuss the basis of the classification of lymphomas –Know the.
Generation of antibodies and T cell receptors by V(D)J recombination Lymphocyte development: generation of cells with functional and useful antigen receptors.
Antibodies and T Cell Receptor Genetics 2011
Comparison of IHC, FISH and RT-PCR for the Detection of EML4-ALK Translocation Variants in Non-Small Cell Lung Cancer Michelle L. Wallander 1, Katherine.
Normal haemopoiesis. ABNORMALITIES IN THE HEMOPOIETIC SYSTEM CAN LEAD TO HEMOGLOBINOPATHIES HEMOPHILIA DEFECTS IN HEMOSTASIS/THROMBOSIS HEMATOLOGICAL.
GASTROINTESTINAL LYMPHOMAS Boudová, Fakan, Mukenšnabl, Daum Vaněček, Šíma, Němcová, Michal PLZEŇ.
MOLECULAR GENETICS and LEUKEMIA Clive S. Zent M.D. Division of Hematology/Oncology.
Molecular Diagnostics
Assessment of monoclonality in large B cell non-Hodgkins lymphoma
Simple-Sequence Length Polymorphisms SSLPs Short tandemly repeated DNA sequences that are present in variable copy numbers at a given locus. Scattered.
Non Hodgkin”s Lymphoma -- Histology appearance -- Cell of orgin -- Immunophenotype -- Molecular biology -- Clinical featres -- Prognosis -- Out-come of.
ANTIBODY DIVERSITY II. Macfarlane Burnet ( ) Macfarlane Burnet ( ) CLONAL SELECTION THEORY Antibodies are natural products that appear.
R4 고원진 / 백선경 교수님 JOURNAL OF CLINICAL ONCOLOGY Volume 29, Number 14, May 2011 The Gray Zone Between Burkitt’s Lymphoma And Diffuse Large B-Cell Lymphoma.
Chapter 12 The diseases of Hematopoietic and Lymphoid System Liu weiping Department of Pathology West China School of Medicine Sichuan University.
Helicobacter pylori and Gastric Lymphoma
Sabine Franke, PhD CHU Ulg Liège, Centre for Human Genetics 15. April 2016 ULG Acquired alterations of IGH and TCR loci in.
GASTROINTESTINAL MALT LYMPHOMA Scott R. Owens, M.D.
by Elaine S. Jaffe, Nancy Lee Harris, Harald Stein, and Peter G
Simple-Sequence Length Polymorphisms
GENETIC BIOMARKERS.
Volume 204, Issue 1, Pages (January 2011)
Effectiveness of Capillary Electrophoresis Using Fluorescent-Labeled Primers in Detecting T-Cell Receptor γ Gene Rearrangements  Timothy C. Greiner, Ronald.
Detection of TMPRSS2-ETS Fusions by a Multiprobe Fluorescence in Situ Hybridization Assay for the Early Diagnosis of Prostate Cancer  Qi-Peng Sun, Liao-Yuan.
Immunogenetics Lecture 3: TcR.
Detection of TMPRSS2-ETS Fusions by a Multiprobe Fluorescence in Situ Hybridization Assay for the Early Diagnosis of Prostate Cancer  Qi-Peng Sun, Liao-Yuan.
CHU Ulg Liège, Centre for Human Genetics
Adam Bagg  The Journal of Molecular Diagnostics 
Detection of Clonally Restricted Immunoglobulin Heavy Chain Gene Rearrangements in Normal and Lesional Skin  Minakshi Nihal, Debra Mikkola, Gary S. Wood 
High BCL6 expression predicts better prognosis, independent of BCL6 translocation status, translocation partner, or BCL6-deregulating mutations, in gastric.
Isothermal Multiple Displacement Amplification
Focus on lymphomas Cancer Cell
Harvey A. Greisman, Noah G. Hoffman, Hye Son Yi 
IgH PCR of Zinc Formalin-Fixed, Paraffin-Embedded Non-Lymphomatous Gastric Samples Produces Artifactual “Clonal” Bands Not Observed in Paired Tissues.
B-Cell Clonality Determination Using an Immunoglobulin κ Light Chain Polymerase Chain Reaction Method  Reetesh K. Pai, Artemis E. Chakerian, John M. Binder,
FISH Analysis for the Detection of Lymphoma-Associated Chromosomal Abnormalities in Routine Paraffin-Embedded Tissue  Roland A. Ventura, Jose I. Martin-Subero,
Association of Clinical Status of Follicular Lymphoma Patients after Autologous Stem Cell Transplant and Quantitative Assessment of Lymphoma in Blood.
Detection of Genetic Alterations by ImmunoFISH Analysis of Whole Cells Extracted from Routine Biopsy Material  Göran Mattsson, Soo Yong Tan, David J.P.
CRISPR/Cas9 Technology–Based Xenograft Tumors as Candidate Reference Materials for Multiple EML4-ALK Rearrangements Testing  Rongxue Peng, Rui Zhang,
Molecular Diagnostic Approach to Non-Hodgkin's Lymphoma
Undifferentiated Small Round Cell Sarcomas with Rare EWS Gene Fusions
Janice M. Spence, Paul G. Rothberg, Nancy Wang, W. Richard Burack 
Allison M. Cushman-Vokoun, Solomon Connealy, Timothy C. Greiner 
Successful Application of a Direct Detection Slide-Based Sequential Phenotype/Genotype Assay Using Archived Bone Marrow Smears and Paraffin Embedded.
N. Scott Reading, Stephen D. Jenson, Jeffrey K. Smith, Megan S
Increased Junctional Diversity in Fetal B Cells Results in a Loss of Protective Anti- Phosphorylcholine Antibodies in Adult Mice  Cindy L Benedict, John.
Ming-Tseh Lin, Li-Hui Tseng, Roy G. Rich, Michael J
BIOMED-2 Multiplex Immunoglobulin/T-Cell Receptor Polymerase Chain Reaction Protocols Can Reliably Replace Southern Blot Analysis in Routine Clonality.
Introduction & haematological malignancies
Volume 36, Issue 4, Pages (November 2009)
Presentation transcript:

GENETIC MARKERS IN LYMPHOMA a practical overview P. Heimann Dpt of Medical Genetics Erasme Hospital - Bordet Institute

B and T cell monoclonalities Rearrangement of immunoglobin and TCR genes may help to establish the malignant nature of a lymphoproliferative lesion Identification of non-random chromosomal abnormalities t(14;18) or t(11;14) translocations in FL and MCL respectively allow lymphoma subtype classification

B and T cell monoclonality what does that mean?

During early lymphoid development, the genes encoding antigen receptor undergo rearrangement example of the Ig heavy chain locus (IgH) Heavy chain Light chain

Schematic diagram of IgH gene rearrangements : indicate the primers location for PCR method

Schematic representation of mono and polyclonal populations detected by PCR. - monoclonal population implies malignant process - polyclonal population implies benign lymphoid proliferation but... the rule is not absolute!

B and T cell monoclonalities - PCR Illustration on ethidium-bromide-stained gel B cells Tcells ?* +? *? oligoclonality H2OH2O H2OH2O

B and T cell monoclonalities - PCR Illustration on Genescan polyclonality monoclonality

PCR Advantages: (vs Southern Blot) - simple and faster - requires much less amounts of pathological material - greater quantitative sensitivity - can be applied on DNA paraffin-embedded tissue Disadvantages: (vs Southern Blot) - lower qualitative sensitivity - need to use several different PCR strategies in order to increase the overall detection rate * * genomic sequence in a given antigen receptor may vary significantly from one to another and multiple sets of primers may be required

PCR strategies Necessity to use several sets of primers in order to increase the overall detection rate (~90 %) of the PCR method: FR3 -JH FR1c-JH FR1f-JH,... This detection rate varies according to the underlying disorders

Detection rates by PCR according to the subtype of B-cell neoplams - SLL~ 100 % - MCL~ 100 % - DLBCL~ 60 % - FL~ 50 %

PCR - Pitfalls False negative: - chromosomal translocations into the IgH locus (in FL or DLCL) - Somatic hypermutation (in FL and DLCL) - partial D-J rearrangements (in immature malignancies) - no VDJ rearrangement produced (in immature malignancies) - failure of the IgH primers to recognize the VH segment involved False positive: - very weak amount of DNA - reactive lymphoid populations

Rules to known (1) - Genotype does not correspond to phenotype ! Lineage infidelity of Ig and TCR gene rearrangements (“Illegitimate rearrangements”): % of lymphoblastic B cell malignancies % of lymphoblastic T cell malignancies. - ~10% of mature B and T cell malignancies. Therefore, Ig and TCR gene rearrangements should not be systematically used as markers for B and T cell lineages, respectively.

Rules to known (2) - Monoclonality is not always equivalent to malignancy ! - Clinically benign lymphoproliferations may consist of clonal cell populations. - Although this pitfall is encountered in B cells, it is mainly observed in T cell monoclonality ( cf limited combinatorial diversity of TCR-γ and -δ genes )

Some cases of unequivocal B-cells lymphoma do not generate a clonal signal by PCR despite histological and immulogic evidences of malignancy Any result must be interpreted in view of other findings and clinical informations Rules to known (3)

Chromosomal abnormalities

closely associated with particular morphological subtypes of lymphoma diagnostic markers prognostic/predictive markers molecular targets for rationale therapies mainly chromosomal translocations

Two distinct types of chromosomal translocations at molecular level A. Quantitative changes BCL2-J H, BCL1-J H,… B. Qualitative changes ALK-NPM, API1-MALT

Recurrent genetic abnormalities in lymphoma t(14;18) / BCL2 - J H in follicular lymphoma t(11;14) / Bcl1 - J H in Mantle Zone lymphoma t(11;18)/ API2-MALT1 in Marginal Zone lymphoma del(7q), +3 t(3;14) / BCL6 - J H in Diffuse Large Cell lymphoma t(8;14) / cMYC - J H in Burkitt lymphoma t(2,5) / ALK-NPMin Anaplastic Large Cell Lymphoma

Follicular lymphoma (1) t(14;18)(q32;q21) - BCL2-IgH oncogene overexpression of the antiapoptotic Bcl2 protein cell survival favoring increased genomic instability Follicular lymphoma

Follicular lymphoma (2) t(14;18)(q32;q21) / BCL2 -IgH locus BCL2 locus IgH FISH: « double fusion strategy »

Follicular lymphoma (3) what to know BCL2 overexpression or no BCL2 overexpression 3q27/BCL6 rearrangement grade 1 t(14;18) positive in 80-90% of cases grade 2 grade 3 t(14;18) positive in ± 30 % (mainly grade 3a) t(14;18) negative in ± 70% (mainly grade 3b)

Follicular lymphoma (5) what to know Conventional cytogenetic and/or FISH “golden standard methodologies” PCR: - four known different breakpoints on Bcl2 gene mbrin ~ 45 % of cases mcrin ~ 7 % of cases 3’ UTR in ~ 10 % of cases icrin ~ 10% of cases several sets of primers required - some breakpoints are still unknown

Follicular lymphoma (4) what to know Methods : different levels of qualitative sensitivity FISH> 95% Cytogenetics~ 80-90% PCR BCL2(mbr)-JH40-50% PCR BCL2(mcr)-JH~ 10%

PCR Bcl2-JH in follicular lymphoma Illustration at diagnosisFollow up the persistance of a positive result or a molecular re-emergence after one year of treatment is highly predictive of a clinical relapse.

Follicular lymphoma (5) what to know At diagnosis: CC and/or FISH * Follow up: Quantitative PCR * FISH can be performed on fresh touch print or paraffin-embedded tissue

Mantle Cell lymphoma t(11;14)(q13;q32) - BCL1-IgH oncogene overexpression of the Bcl1/cyclin D1 protein cell cycle activation (G1/S phase) (+ other genetic alterations involving TSG such as p16) mantle cell lymphoma

Mantle cell lymphoma (2) t(11;14)(q13;q32)/BCL1-IgH locus BCL1 locus IgH locus BCL1 locus IgH cyclin D1 overexpression FISH: « double fusion strategy »

Mantle cell lymphoma (3) what to know Conventional cytogenetic and/or FISH “golden standard methodologies” PCR: - one major known breakpoints on Bcl1 gene MTCin ~ 50 % of cases - other breakpoints are heterogeneous and difficult to detect (large target region for possible rearrangement breakpoints)

Mantle cell lymphoma (3) what to know Methods : different levels of qualitative sensitivity FISH> 95% Cytogenetics~ 80% PCR BCL1(MTC)-JH~ 50% RT-PCR ( CyclinD1 overexpression) ~ 100% * * results difficult to interpret

Marginal cell lymphoma (1) Distribution of chromosomal abnormalities according to the three  subtypes MZL of MALT type chromosoma l translocations with site-specificity in terms of their incidence splenic MZL numerical abnormalities (mainly trisomies 3, 7, 18) nodal MZL numerical and structural abnormalities: del(7q),+3

Marginal cell lymphoma (2 ) MALT type t(11;18)(q21;q21) API2-MALT % stomach intestine lung t(14;18)(q32;q21) MALT1-IgH 20% salivary gland ocular adnexa skin, liver, lung t(1;14)(p22;q32) BCL10-IgH1-2% stomach, lung t(3;14)(p14;q32) FOXP1-IgH5% thyroid, skin, ocular adnexa

t(11;18)(p21;q21) / API2-MALT in gastric MALT lymphoma gastric MALT with t(11;18) do not respond to Helicobacter pylori antibiotic WT MALT1 dual color (green red) MALT1 probe FISH: “break-apart probe strategy” wild type MALT1: 1 yellow spot splited MALT1: 1 green and 1 red

splenic Marginal cell lymphoma (3) 46,XX,del(7)(q22q32) del(7q) control probe deleted region : 7q31

Diffuse Large B cell lymphoma (1) t(3;14)(q27;q32) BCL6-IgH oncogene t(3q27;v) BCL6-non IgH oncogene in 30-40% of DLBCL BCL6 oncogene overexpression* cell survival and proliferation DLBCL * high BCL6 overexpression better outcome

Diffuse Large B cell lymphoma (2) Illustration BCL6 probe t(3;14)(q27;q32) BCL6-IgH FISH: “break-apart probe strategy”